• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Calgenex Cites Recent Study Showing Triglyceride Lowering Benefits of Omega-3s

Posted on: Thursday, 8 February 2007, 12:00 CST

Calgenex Corporation cites a recent study published in the Journal of the American College of Nutrition further substantiating the American Heart Association's recommended cardio-protective dose of omega-3 fatty acids in the lowering of triglycerides in patients with coronary artery disease (CAD).

The study, conducted through Kaiser Permanente Colorado, involved 116 patients with coronary artery disease who had triglycerides greater than 200 mg/dL. Approximately 90 percent of the patients were taking statin drugs. Statins are the most widely prescribed drugs in the world. While statins have been shown to be effective at lowering levels of LDL, or "bad" cholesterol, they have not shown significant impact on levels of HDL, or "good" cholesterol or triglycerides. Therefore, patients with CAD generally require a combination of a lipid lowering therapy, such as a statin along with a triglyceride-lowering agent. The current study supports the efficacy of Omega 3s as an all natural triglyceride lowering agent.

The study results reflected well for omega-3 fish oil products that contain the natural ratios of EPA to DHA with reference to heart health and the well known triglyceride lowering effect of omega-3s. The aim of the prospective, randomized, double blind study was to compare DHA to DHA + EPA in patients with CAD and triglycerides greater than 200 mg/dL.

Subjects were randomized to either 1000 mg of DHA or 1252 mg of DHA + EPA for eight weeks. A total of 116 subjects were enrolled; 57 in the DHA group and 59 in the DHA + EPA group. Baseline characteristics were similar between the groups.

In the study, triglycerides were lowered an average of 21.8 percent in the DHA only group and 18.3 percent in the DHA + EPA, leading the researchers to conclude that no significant difference in efficacy exists between DHA and DHA + EPA.

Calgenex Corporation, a new entrant to the nutraceutical market, recently introduced Omeganol, the first all natural dietary supplement combining Omega 3s (DHA + EPA) and tocotrienols to manage both cholesterol and triglycerides. By combining the triglyceride-lowering properties of omega-3 fatty acids (essential fats found in oily, cold-water fish such as sardines and anchovy) with the cholesterol-balancing activity of tocotrienols (members of the vitamin E family that naturally occur in palm fruit and annatto flower), Omeganol offers a new alternative for managing cholesterol and triglycerides without the potential negative side effects of certain pharmaceutical drugs (www.omeganol.net).

"Most supplements on the market either target cholesterol or triglycerides -- which means they only supply one piece of the heart health puzzle," stated Joe Jacobs, M.D., consulting medical director for Calgenex and former director of the Office of Alternative Medicine at the National Institutes of Health. "Omeganol is a truly unique product that represents a safe, natural alternative for managing cholesterol and triglycerides."

"Many people are looking for ways to manage blood lipids naturally," stated Grant Carlson, CEO and Founder of Calgenex Corporation. "We are encouraged by the results of the current study demonstrating that the American Heart Association's recommended cardioprotective dose of Omega 3s can also significantly lower triglycerides thereby offering the public a safe and natural alternative."

Founded in 2006, Calgenex Corporation manufactures and markets dietary supplements, topical OTC drugs and personal care products specially formulated to combat the effects of soft tissue calcification and inflammation.

Calgenex is located at 9950 Princess Palm Avenue, Suite 320 in Tampa, Florida. For more information about the company or its products, please visit http://www.calgenex.com/, phone 813-623-5268, or email gcarslon@calgenex.com.

Source: Business Wire

More News in this Category